|1.||Price, Ric N: 1 article (01/2014)|
|2.||Anstey, Nicholas M: 1 article (01/2014)|
|3.||Kenangalem, Enny: 1 article (01/2014)|
|4.||Tjitra, Emiliana: 1 article (01/2014)|
|5.||Fobia, Wendy: 1 article (01/2014)|
|6.||Sugiarto, Paulus: 1 article (01/2014)|
|7.||Poespoprodjo, Jeanne Rini: 1 article (01/2014)|
|8.||Lampah, Daniel A: 1 article (01/2014)|
|9.||Islam, M N: 1 article (12/2013)|
|10.||Rahman, M R: 1 article (12/2013)|
01/01/2014 - "Of the 1217 women admitted with malaria in the second and third trimesters without an impending adverse outcome, those treated with DHP were more likely to be discharged with an ongoing pregnancy compared to those treated with a non-ACT regimen (Odds Ratio OR = 2.48 [1.26-4.86]); p = 0.006. "
12/01/2013 - "The two ACT regimen, AA and AL had no significant difference in efficacy and safety for treatment of Uncomplicated Malaria in Bangladesh. "
08/01/2009 - "Artemether-lumefantrine (AL; Coartem, Riamet) is the first fixed-dose artemisinin combination therapy (ACT) regimen to be manufactured under Good Manufacturing Practice conditions, and is the most widely adopted ACT regimen used in malaria control programs. "
|1.||artemether-lumefantrine combination (Coartem)